8.30 Virtual Morning Networking

9:00 am Chair’s Opening Remarks

9:10 am Exploring Mechanistic Approaches to Treating Neuropsychiatric Disorders such as Depression, Autism & Cognitive Impairment

Synopsis

• Analyzing preclinical data for ANAVEX1-41
• Discovering the links between compound classes and how we can exploit these

9:35 am Leveraging Informatics & Digital Technologies for Precision & Predictive Neuropsychiatric Diseases

  • Vaibhav Narayan Vice President, Data Science, Neuroscience Therapeutic Area, Janssen R&D

Synopsis

• Implementing wearable sensors and smartphones for early diagnosis and disease course monitoring
• Developing novel ‘point-of-need’ tools and technologies for management of adherence and prediction of relapse in patients with schizophrenia

10:00 am Exploring Boehringer-Ingelheim’s Commitment to Bringing First-inClass Medicines to Neuropsychiatric Patients

  • Christian Thomsen Global Head, CNS Business Development & Licensing, Boehringer Ingelheim

Synopsis

• A focus on innovative approaches to modulate maladaptive neurocircuits and
neural network activity across symptom domains
• Key indications include Schizophrenia, Major Depressive disorders and Impulsivity
disorders

10:25 am Live Q&A

10.40 Virtual Speed Networking Break

Deep Dive into Approaches for Treating Post Traumatic Stress Disorder, a Truly Unmet Medical Need

11:30 am BNC210: A Negative Allosteric Modulator of Alpha7 Nicotinic Acetylcholine Receptor in Development for the Treatment of Anxiety, Depression & Post Traumatic Stress Disorder

Synopsis

• Why is this novel target relevant for treatment of anxiety, depression and PTSD?
• Clinical data demonstrating target engagement from EEG studies and proof-ofbiology in healthy subjects
• Combination of imaging and behavioral studies in GAD patients comparing with lorazepam
• PTSD pharmacometric analysis
• Defining the path forward

11:55 am Developing a PTSD Therapeutic – Phase 3 Clinical Development

Synopsis

  • Targeting disturbed sleep in PTSD to facilitate recovery
  • Role of time-since-trauma in treatment responsiveness
  • Trimodal mechanism of action of cyclobenzaprine; enhancement by dynamic diurnal pharmacokinetic delivery

12:20 pm Live Q&A

12.50 Networking Lunch

Deep Dive into Schizophrenia Drug Development

1:40 pm Investigating How Altered C4 Expression Contributes Directly to Schizophrenia Pathogenesis

Synopsis

  • Exploring how increased expression of schizophrenia associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction
  • Developing a transgenic mouse model to establish more translation approaches to study how we can revere schizophrenia associated phenotypes
  • Showing schizophrenia as a neurodevelopmental disorder and dissecting how the developmental trajectory of the brain changes

2:05 pm Emergence of the Next Generation of Anti-Psychotics

  • Steve Paul CEO and Chairman, Karuna Therapeutics, Inc

Synopsis

• Diving into KarXT, a novel medicine for treating psychosis
• Preferentially targeting and stimulating muscarinic receptors in the central nervous system and leaving those in the peripheral tissues unaffected
• Sharing clinical data and outlining the steps involved in initiating the Phase III trial

2:30 pm Schizophrenia, A New Treatment Option for Patients

  • Sharon Mates Chairman, President & CEO, Intra-Cellular Therapies, Inc.

Synopsis

• Efficacy and safety of a new antipsychotic

2:55 pm Linking Innate Immunity, Neuroinflammation & the Gut Brain Axis to the Development of Psychiatric Disorders

  • Giulio Maria Pasinetti Saunders Family Chair & Professor of Neurology, Psychiatry & Neuroscience,Geriatrics & Adult Development, Icahn School of Medicine, Mount Sinai

Synopsis

  • Discuss evidence highlighting how psychological stress through inflammasome complexes integrates signals in innate immune cells (microglia) to promote neuroinflammation
  • Delving into the relationship between inflammatory responses and stress induced psychiatric disorders such as major depressive disorders (MDD)
  • Bioactive dietary prebiotic metabolites that influence innate immune crosstalk, promoting resilience to depression and anxiety by synbiotic treatments
  • Testing synbiotic biomarkers in the human model Trier Social Stress Test (TSST)

3:20 pm Live Q&A

  • Steve Paul CEO and Chairman, Karuna Therapeutics, Inc
  • Alberto Cruz-Martin Assistant Professor of Biology, Boston University
  • Sharon Mates Chairman, President & CEO, Intra-Cellular Therapies, Inc.
  • Giulio Maria Pasinetti Saunders Family Chair & Professor of Neurology, Psychiatry & Neuroscience,Geriatrics & Adult Development, Icahn School of Medicine, Mount Sinai

Innovative Approaches to Understanding Psychiatric Disorders to Drive More Clinically Effective Drugs

4:00 pm Chair’s Closing Remarks